Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Duck Tembusu virus (DTMUV) is an emerging avian-pathogenic mosquito-borne flavivirus that primarily affects ducks, causing significant economic losses in the poultry industry across Southeast Asia and China [3, 6]. First identified in 2010, the virus is the causative agent of duck Tembusu virus disease, characterized by acute egg drop syndrome in laying ducks and severe neurological disorders in ducklings [6, 7, 14]. The DTMUV genome is a single-stranded positive-sense RNA that encodes a polyprotein cleaved into structural proteins (C, prM, E) and non-structural proteins (NS1 to NS5) [10, 12]. The envelope (E) protein is the primary surface protein responsible for host cell receptor binding and membrane fusion, making it a key target for neutralizing antibodies and entry inhibitors [4, 10, 13]. Non-structural proteins such as NS3 and NS5 are essential for viral replication and have been shown to modulate host processes like autophagy and innate immune signaling to facilitate infection [1, 6, 12]. Experimental antiviral strategies have explored the use of compounds like curcumin and epigallocatechin-3-gallate (EGCG) to inhibit viral entry and replication [4, 8]. Additionally, modulating host pathways such as the interferon response and autophagy has shown potential in reducing viral load in vivo [1, 4]. While primarily an avian pathogen, the detection of neutralizing antibodies in humans suggests a potential for zoonotic transmission [15]. The rapid spread and high morbidity of DTMUV necessitate the development of specific vaccines and effective therapeutic interventions [6, 16]. Overall, DTMUV represents a significant veterinary challenge with potential public health implications [3, 15].
Inhibition of viral entry and adsorption; inhibition of post-adsorption viral replication; modulation of host autophagy pathways; upregulation of type I interferon signaling.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Duck Tembusu virus (DTMUV) (DTMUV).